Josep Quer Sivila I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies. Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Josep Quer Sivila LinkedIn Twitter Orcid Email Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies.
Senior Researcher at Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus from 2021 (indefinite contract). Associate Professor at the Biochemistry and Molecular Department of the UAB from 2021 to present (3933001435 Y0LOU0146). Accredited researcher at CIBERehd (2010-prest). Accredited as Professor (Catedrático) from AQU (Generalitat de Catalunya) from 2023. Academic background: Bachelor in Biology from UB (1981-86). PhD in Biology from UAB (1994) with extraordinary award. Postdoctoral stay in the University of California at San Diego USA (1994-96). Member of Ciberehd since 2007-act. Associate Professor (AP) of Immunology, UB (1988-89); AP Medicine, UAB (2003-18); AP of Biochemistry and Molecular Biology, UAB (2021-pres.). General Coordinator Master in "Translational Biomedical Research" VHIR-UAB (2020-pres.). Professor and coordinator of Module 1 Master in "Translational Biomedical Research" VHIR-UAB since 2014-pres. Scientific and professional activities: Projects: Since 2016, he has led 10 overlapping competitive financed projects, serving as the Principal Investigator (PI) in eight national projects and as the co-IP of the local-node in two European Union projects. Thesis: 6 PhD thesis directed, and 3 under development. Papers and reviews: 154 papers; 8 book chapters & 1 book published in 2023. Meetings participation: 220, 66 of them as invited speaker. Other merits: Member Coordinator Committee “Strategic Plan for Tackling hepatitis C (PEAHC) Spanish Ministry of Health; Treasurer Spanish Society of Virology (SEV) (2009-pres.); Member of scientific societies (ESV;AEEH;SCB) and of Alliance for the Elimination of Hepatitis in Spain (AEHVE). Organizing Committee of International Symposium Fundación Ramón Areces (2013); and SEV National Meetings (2013-2015-2017-2019-2022). Impacts printed, digital, radio and TV. NGS-2010: 32 impacts; HCV-2015: 69 impacts; SARS-CoV-2 – 2020-23: 90 impacts. Awards: Ciudad de Barcelona (1996); Best ideas Diario Medico (2015); Premi Ciència i Tecnologia Diari Regió7-Prensa Ibérica (2020). Metrics: h-index:41 (scholar), 35 (WoS), 37 (Scopus); i10-index: 116; Citations (WoS): 8371; Views: >40000. ORCID: 0000-0003-0014-084X // WOS ResearcherID A-6741-2012 // SCOPUS ID: 7004592398 Social media: Linkedin: Josep Quer Twitter (X): @JosepQuerSivila / @VirusLabQ (Virus Lab by Dr. Josep Quer) / @HepatitisSEV
Proyectos Identification of diagnostic and prognostic markers of hepatocellular carcinoma (HCC) in Extracellular Vesicles, using a minimally invasive method, and based on deep-sequencing (NGS) IP: Josep Quer Sivila Colaboradores: Sergi Colomer Castell, Miriam Izquierdo Sans Entidad financiadora: Fundació Institut de Recerca HUVH Financiación: 50649.27 Referencia: VHIR/BEQUESPREDOC/2020/COLOMER Duración: 01/05/2021 - 30/04/2024 Whole genome SARS-CoV-2 sequencing in Covid-19 mild and severe patients to identify virulence and prognostic factors IP: Josep Quer Sivila Colaboradores: - Entidad financiadora: Generalitat de Catalunya - Departament de Salut Financiación: 298141.88 Referencia: 6_6 Duración: 08/04/2020 - 31/12/2020 Identificación de marcadores de diagnóstico y pronóstico de carcinoma hepatocelular (HCC) en vesiculas extracelulares, mediante un método mínimamente invasivo, basado en secuenciación masiva (NGS) IP: Josep Quer Sivila Colaboradores: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Ariadna Rando Segura, Damir Garcia Cehic Entidad financiadora: Instituto de Salud Carlos III Financiación: 165770 Referencia: PI19/00301 Duración: 01/01/2020 - 30/06/2023 DESARROLLO DE APLICACIONES DIAGNÓSTICAS EN INFECCION POR VHC BASADAS EN SECUENCIACIÓN DE MOLECULA ÚNICA EN TIEMPO REAL (SMRT-NNGS). IP: Josep Quer Sivila Colaboradores: Lluis Castells Fusté, Silvia Sauleda Oliveras, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Marta Bes Maijo, Cristina Dopazo Taboada Entidad financiadora: Instituto de Salud Carlos III Financiación: 153065 Referencia: PI16/00337 Duración: 01/01/2017 - 31/05/2020 Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3 Página 4 Página 5 … Siguiente página › Última página »
